This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Development of a high resolution melting analysis assay for rapid identification of JAK2 V617F missense mutation and its validation
Experimental Hematology & Oncology Open Access 30 April 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162–2168.
Saharinen P, Vihinen M, Silvennoinen O . Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 2003; 14: 1448–1459.
James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148.
McClure R, Mai M, Lasho T . Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 2006; 20: 168–171.
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
Kralovics R, Skoda RC . Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev 2005; 19: 1–13.
Ishii T, Bruno E, Hoffman R, Xu M . Involvement of various hematopoietic cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 2006, [E-pub ahead of print].
Schnittger S, Bacher U, Kern W, Schroder M, Haferlach T, Schoch C . Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia 2006, [E-pub ahead of print].
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grünebach, F., Bross-Bach, U., Kanz, L. et al. Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera. Leukemia 20, 2210–2211 (2006). https://doi.org/10.1038/sj.leu.2404419
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404419
This article is cited by
-
Development of a high resolution melting analysis assay for rapid identification of JAK2 V617F missense mutation and its validation
Experimental Hematology & Oncology (2019)
-
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders
Leukemia (2008)
-
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
Leukemia (2008)
-
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
Leukemia (2008)
-
Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera
Leukemia (2007)